click here for details Licensing the RetroNectin® Method Takara Bio holds world-wide exclusive rights for the highly efficient retrovirus-mediated transduction method (RetroNectin® method), which is used in medical institutions and private corporations over the world conducting clinical trials in gene therapy.
click here for details Gene Therapy Development We are collaborating with the National Cancer Center in clinical development of HSV-TK gene therapy in hematopoietic tumors, and Mie University in clinical development of TCR gene therapy. We are involved in the development of these gene therapy projects.
click here for details Cell Therapy Development Takara Bio is involved in clinical development of a cancer immunotherapy using the RetroNectin® expansion-culture system, as well as providing support for other cancer immunotherapies.
return to top
click here for details
Licensing the RetroNectin® Method
click here for details
Gene Therapy Development
click here for details
Cell Therapy Development
